| Literature DB >> 31782186 |
Yasuhiro Nakamura1, Jun Asai2, Hiroshi Igaki3, Takashi Inozume4, Kenjiro Namikawa5, Ayato Hayashi6, Satoshi Fukushima7, Taku Fujimura8, Takamichi Ito9, Keisuke Imafuku10, Ryota Tanaka11, Yukiko Teramoto1, Akane Minagawa12, Takuya Miyagawa13, Azusa Miyashita7, Makoto Wada2, Hiroshi Koga12, Makoto Sugaya14.
Abstract
With consideration of the ongoing developments in treatment options for cutaneous melanoma, the Japanese Skin Cancer Society published the first guidelines for cutaneous melanoma in 2007 and later revised them in 2015. Here, we report on an English version of the 2019 Japanese Melanoma Guidelines. In this latest edition, all processes were carried out according to the Grading of Recommendations, Assessment, Development and Evaluation system. A comprehensive published work search, systematic review and determination of recommendations in each clinical question were performed by a multidisciplinary expert panel consisting of dermatologists, a plastic and reconstructive surgeon, and a radiation oncologist. The advent of novel agents, such as immune checkpoint inhibitors and molecular-targeted agents, has drastically changed the nature of treatment for adjuvant and advanced-stage diseases among melanoma patients worldwide. Additionally, recent reports of clinical trials regarding surgical procedures and a better understanding of molecular biology and tumor immunology in clinical types of melanoma have had an impact on clinical practise. Based on these viewpoints, eight relevant clinical questions were raised in this report that aim to help clinicians select the appropriate therapeutic approach.Entities:
Keywords: cutaneous melanoma; grade system; guidelines; immune checkpoint inhibitor; molecular-targeted agent
Mesh:
Year: 2019 PMID: 31782186 DOI: 10.1111/1346-8138.15151
Source DB: PubMed Journal: J Dermatol ISSN: 0385-2407 Impact factor: 4.005